CAC 40 Up 1.25% On Trade Deal Optimism

French equities, led by the CAC 40, advanced 1.24% for a third consecutive session, buoyed by optimism surrounding a potential U.S.-EU trade agreement. This market strength prevailed despite U.S. President Trump's recent threats of new tariffs, including a 50% levy on copper imports and up to 200% on pharmaceutical exports to the U.S. Individual stock performance saw EssilorLuxottica surge nearly 6% on reports of Meta acquiring a stake, while major banks like Societe Generale and BNP Paribas also posted significant gains.

Analysis

The French equity market is demonstrating notable resilience, with the CAC 40 index advancing 1.24% to 7,862.98 in its third consecutive session of gains. This upward momentum is primarily fueled by investor optimism regarding a potential U.S.-EU trade agreement, which is currently overriding concerns stemming from new U.S. tariff threats. Despite the announcement of a 50% levy on copper imports and a proposed 200% tariff on pharmaceuticals, the market's focus remains on the positive macro outlook. The impact of the pharmaceutical tariff threat appears mitigated by its delayed implementation timeline of 12 to 18 months, resulting in only a marginal decline for Sanofi. Company-specific catalysts are also driving performance, most significantly EssilorLuxottica's nearly 6% surge on reports of Meta acquiring a sub-3% stake. The rally exhibits broad-based strength, with the banking sector showing particular buoyancy as Societe Generale and BNP Paribas gained 3.5% and 2.5% respectively, and numerous other blue-chips like Airbus and ArcelorMittal registered gains between 1% and 2%.

Key Decisions for Investors

• Investors should assess EssilorLuxottica's valuation following the nearly 6% gain, as the strategic investment by Meta could signal a new long-term growth vector for the company.
• Monitor developments in U.S.-EU trade negotiations closely, as the market's current positive sentiment is heavily contingent on a favorable outcome and could reverse quickly on negative news.
• For positions in the pharmaceutical sector, such as Sanofi, it is crucial to price in the long-term risk of potential U.S. tariffs, even with the delayed timeline, as this remains a significant future headwind.
• The strength in French banking stocks reflects a risk-on appetite, but this optimism is tied to a speculative trade deal; consider trimming exposure or hedging if confidence in a deal wanes.